Evommune, Inc.

Data Presentation Highlights:

•

EVO301 met primary endpoint: EVO301 met the trial’s primary endpoint, achieving a 55% least-squares (LS) mean reduction in EASI from baseline at Week 12 compared with 22% on placebo (p<0.01), eight weeks after the last dose. Statistically significant separation from placebo was observed as early as Week 4 (41% vs. 18%) and maintained through Week 8 (50% vs. 16%) and Week 12 (p<0.01 at each time point).

•

Early, durable EASI-50 and EASI-75 responses with only two dose administrations: EVO301 demonstrated significant EASI-50 separation from placebo as early as Week 4, with responses sustained and continuing to deepen through Week 12, eight weeks after the last dose. At Week 12, 63% of EVO301-treated patients achieved EASI-50 compared with 23% on placebo, and EASI-75 responses showed increasing separation from placebo over time, reaching 29% vs. 9% on placebo at Week 12, consistent with the range of rates observed with marketed AD biologics after a single dose administered at baseline and Week 4.

•

Optimized pharmacokinetics: EVO301 demonstrated a favorable PK profile consistent with Phase 1 supporting a Q4‑week dosing regimen and the potential for every-8-to-12-week maintenance dosing.

•

Mechanistic biomarker evidence: Exploratory analyses showed reductions in the Th2 markers CCL-17 (TARC) and CCL-22, including approximately 75% reductions in patients with high baseline TARC. EVO301 also reduced Th1, Th17 and Th22 markers, including IL-22, a key regulator of skin barrier function.

•

Favorable safety and tolerability profile: EVO301 was well tolerated, with no treatment-related serious or severe adverse events, no discontinuations due to adverse events, no clinically significant laboratory abnormalities, and no conjunctivitis, a common adverse event reported with AD biologics. Treatment-related adverse events occurred in 10.4% of EVO301-treated patients compared with 13.6% on placebo.